5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.46▲ | 1.45▲ | 1.45▲ | 1.49▼ | 1.86▼ |
MA10 | 1.46▲ | 1.44▲ | 1.44▲ | 1.51▼ | 2.32▼ |
MA20 | 1.45▲ | 1.44▲ | 1.47▼ | 1.85▼ | 3.45▼ |
MA50 | 1.44▲ | 1.48▼ | 1.45▲ | 2.40▼ | 4.93▼ |
MA100 | 1.44▲ | 1.46▼ | 1.63▼ | 3.58▼ | 4.33▼ |
MA200 | 1.48▼ | 1.68▼ | 2.07▼ | 4.94▼ | 6.57▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▲ | 0.006▲ | 0.000▼ | 0.004▲ | -0.186▼ |
RSI | 56.442▲ | 51.758▲ | 48.614▼ | 30.783▼ | 23.796▼ |
STOCH | 56.667 | 69.687 | 58.800 | 29.635 | 6.279▼ |
WILL %R | -33.333 | -14.286▲ | -57.143 | -80.874▼ | -95.270▼ |
CCI | 35.461 | 113.208▲ | 47.887 | -72.402 | -126.353▼ |
Wednesday, April 16, 2025 09:05 PM
BRISBANE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with ...
|
Wednesday, April 16, 2025 09:05 AM
BRISBANE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with ...
|
Tuesday, April 15, 2025 04:43 AM
The last time I wrote about Annexon (NASDAQ:ANNX) it was with respect to a Seeking Alpha article entitled "Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place".
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
17/04/25 | 1.42 | 1.47 | 1.405 | 1.46 | 870,816 |
16/04/25 | 1.53 | 1.55 | 1.40 | 1.43 | 1,154,865 |
15/04/25 | 1.54 | 1.675 | 1.475 | 1.54 | 1,975,832 |
14/04/25 | 1.55 | 1.595 | 1.48 | 1.53 | 1,319,214 |
11/04/25 | 1.38 | 1.53 | 1.35 | 1.49 | 1,564,264 |
10/04/25 | 1.44 | 1.47 | 1.285 | 1.38 | 1,559,725 |
09/04/25 | 1.52 | 1.525 | 1.30 | 1.42 | 5,209,745 |
08/04/25 | 1.75 | 1.77 | 1.54 | 1.54 | 1,580,775 |
07/04/25 | 1.61 | 1.67 | 1.52 | 1.63 | 3,048,632 |
04/04/25 | 1.76 | 1.83 | 1.66 | 1.69 | 1,851,533 |
|
|
||||
|
|
||||
|
|